Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales

MT Newswires Live

2024/12/20

Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.

"Securing access to Pedmarqsi is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.

Price: 5.89, Change: +0.05, Percent Change: +0.86

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492428481"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492428481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492428481?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492428481","market":"us","top_or_hot":-1,"title":"Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales","media":"MT Newswires Live","content":"<html><body><p> Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.</p><p>\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.</p><p>Price: 5.89, Change: +0.05, Percent Change: +0.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-20 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.</p><p>\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.</p><p>Price: 5.89, Change: +0.05, Percent Change: +0.86</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FENC","symbol_name":"Fennec Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492428481","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492428481","pubTimestamp":1734710251,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fennec Pharmaceuticals  said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.Price: 5.89, Change: +0.05, Percent Change: +0.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FENC":"Fennec Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Fennec Pharmaceuticals的儿童听力损失药物在英格兰和威尔士获得研究所的认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FENC":0.9},"content_text":"Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.Price: 5.89, Change: +0.05, Percent Change: +0.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}